Fascioliasis

Summary

Fascioliasis (MONDO:0004668) is a disease and 3 clinical trials. Top therapeutic interventions include triclabendazole and oxfendazole. A subtype of helminthiasis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	fascioliasis
Mondo ID	MONDO:0004668
EFO	EFO:1001324
MeSH	D005211
DOID	DOID:885
ICD-10-CM	B66.3
ICD-11	656408831
NCIT	C128387
SNOMED CT	82308007
UMLS	C0015652
MedGen	41969
Is cancer (heuristic)	no

Also known as: Fasciolosis · infection by fasciola · sheep liver fluke infection

Disease family

This is a subtype of helminthiasis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › parasitic infectious disease › helminthiasis › fascioliasis

Related subtypes (21): acanthocephaliasis, heterophyiasis, metagonimiasis, fasciolopsiasis, monieziasis, clonorchiasis, dicrocoeliasis, echinostomiasis, fascioloidiasis, gnathomiasis, hymenolepiasis, necatoriasis, Nematoda infectious disease, opisthorchiasis, paragonimiasis, trichostrongyloidiasis, schistosomiasis, filariasis, angiostrongyliasis, intestinal helminthiasis, Cestode infectious disease

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

1 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Triclabendazole	Approved (phase 4)

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE4	1
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04230148	PHASE4	COMPLETED	Study of Safety, Tolerability and Clinical Outcomes of Egaten in Fascioliasis Patients (6 Years of Age or Older).
NCT06367361	PHASE2	NOT_YET_RECRUITING	One and Two Doses of Oxfendazole Versus a Schedule of Two Doses of Triclabendazole in Chronic Fascioliasis
NCT03869788	Not specified	UNKNOWN	Parasitological Evaluation of Fascioliasis in Clinically Suspected Patients .

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
TRICLABENDAZOLE	4	1
OXFENDAZOLE	2	1